Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer

doi:10.3748/wjg.v30.i40.4367

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 40

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (138)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-2)

Sum=68

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=64

Publishing Process of This Article

Item

Count

Browse

Download

Sum=1

Oct 28, 2024 (publication date) through Oct 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Oct 28, 2024; 30(40): 4367-4375
Published online Oct 28, 2024. doi: 10.3748/wjg.v30.i40.4367

Full Size Figure Download Figure

Figure 1 Progression-free survival and overall survival curves for patients with HER2-positive advanced gastric cancer treated with inetetamab combined with the S-1 plus oxaliplatin regimen or trastuzumab combined with the S-1 plus oxaliplatin regimen. A: Progression-free survival curve; B: Overall survival curve. HR: Hazard ratio; CI: Confidence interval.

Citation: Kong Y, Dong Q, Jin P, Li MY, Ma L, Yi QJ, Miao YE, Liu HY, Liu JG. Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. World J Gastroenterol 2024; 30(40): 4367-4375
URL: https://www.wjgnet.com/1007-9327/full/v30/i40/4367.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i40.4367